Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...

An experimental medicine from Vera Therapeutics significantly reduced levels of toxic protein in the urine of patients with ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...

The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

Thousands of people living with chronic kidney disease in England could soon benefit from a new treatment, following final ...